Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Sep 10, 2020
Date Accepted: Sep 10, 2020

The final, peer-reviewed published version of this preprint can be found here:

Correction: mHealth Interventions to Promote Anti-Retroviral Adherence in HIV: Narrative Review

Lee SB, Valerius J

Correction: mHealth Interventions to Promote Anti-Retroviral Adherence in HIV: Narrative Review

JMIR Mhealth Uhealth 2020;8(9):e24250

DOI: 10.2196/24250

PMID: 32931442

PMCID: 7525407

Correction: mHealth Interventions to Promote Anti-Retroviral Adherence in HIV: Narrative Review

  • Stephen B Lee; 
  • Joanne Valerius

ABSTRACT

Antiretrovirals (ARVs) are key in the management of HIV. Although no cure exists, ARVs help patients live healthy lives and prevent transmission to others. Adherence to complex regimens is paramount to outcomes and in avoiding the emergence of drug-resistant viruses. The goal of therapy is to reach an undetectable viral load. However, adherence is a common problem, stemming from issues such as mental health, chaotic home situations, and busy work schedules. Mobile health (mHealth) represents a new approach in improving medication adherence, and multiple studies have been performed in this area.


 Citation

Please cite as:

Lee SB, Valerius J

Correction: mHealth Interventions to Promote Anti-Retroviral Adherence in HIV: Narrative Review

JMIR Mhealth Uhealth 2020;8(9):e24250

DOI: 10.2196/24250

PMID: 32931442

PMCID: 7525407

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.